Sclerostin and chronic kidney disease

Vitamin deficiencies in chronic kidney disease

Endocrine disorders in chronic kidney disease

Background and Objective: Endocrine disorders are common in patients with chronic kidney disease (CKD). The aim of the present study is reviewing available literature to give a deep understanding of complexities of endocrine disorders in chronic kidney disease. Methods: A narrative reviewing method based on the available literature was approached. Findings: Generally, when renal function de...

Etiology and Outcome of Chronic Kidney Disease in Iranian Children

Background Considering the significant geographical and ethnical differences in pattern of incidence, etiology and outcome of chronic kidney disease (CKD), the present study aimed to assess the etiology and outcome of CKD in Iranian children. Materials and Methods In a cross-sectional study etiology and outcome of 372 children aged 3 months to 18 years with CKD was studied during the period 199...

Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder

Sclerostin is a 190-amino-acid glycoprotein that is mainly secreted by osteocytes, and it decreases bone formation by inhibiting the terminal differentiation of osteoblasts and promoting their apoptosis. Sclerostin blocks the Wnt signaling pathway in osteoblasts by binding to low-density lipoprotein receptor-related protein 5/6 (LRP-5/6) receptors. We reviewed the literature detailing the role ...

An update on sclerostin and kidney

Introduction Bone diseases commonly detected in chronic renal failure patients and increases a patient’s risk for cardiovascular calcification, fracture and mortality. Excessive vascular calcification between hemodialysis individuals plays a predictive and contributive role in consequent cardiovascular incidents and all-cause mortality (1,2). The relationship of bone turnover and cardiovascular...